Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

849.63 +20.21 (+2.44%)
Streaming Delayed Price Updated: 11:47 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Dow Dips Over 500 Points, Down For 3rd Straight Session As UnitedHealth Tanks: Greed Index Remains In 'Extreme Fear' Zone
U.S. stocks end lower, Dow falls over 500 points. Fear & Greed index remains in Extreme Fear zone. Eli Lilly & Co. sees sharp rally on trial results. 
Via Benzinga
Topics Stocks
Exposures US Equities
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences. 
Via Benzinga
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
Via The Motley Fool
Stocks Finish The Week Lower Despite Solid Start To Earnings Season
After a volatile couple of weeks in which stocks fluctuated wildly, things seemed to have settled down a bit this week, although the major indexes finished mostly lower. 
Via Talk Markets
Topics ETFs Stocks / Equities
Is Eli Lilly Stock a Buy Right Now?
The pharmaceutical sector could be the next industry to face sweeping tariffs from the Trump administration. 
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Benzinga Bulls And Bears: Netflix, UnitedHealth, Eli Lilly — And Market Volatility Continues
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength. 
Via Benzinga
Topics ETFs
Market Monitor April 18 ( Eli Lilly, Netflix UP, United Health Group, Manpower DOWN)
Wall Street Mostly Lower Amid Trump-Fed Tensions, Nvidia’s Continued Slide 
Via Chartmill
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
Stay informed with the top movers within the S&P500 index on Thursday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035. 
Via Benzinga
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
Analyst downgrades Novo Nordisk, citing Eli Lilly's rising dominance and weak competitive outlook for 2025. 
Via Benzinga
Which S&P500 stocks have an unusual volume on Thursday?
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Thursday. Stay informed about the market activity below. 
Via Chartmill
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Wall Street Rebounds, Eli Lilly Rallies, UnitedHealth Group Plummets: What's Driving Markets Thursday?
Wall Street saw a rebound in risk appetite on Thursday ahead of the long Easter weekend, as President Donald Trump signaled positive momentum in trade negotiations. 
Via Benzinga
Topics Government
Exposures Political
Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential
Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by... 
Via Benzinga
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding. 
Via The Motley Fool
There are notable gap-ups and gap-downs in today's session.
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Why Is Eli Lilly (LLY) Stock Rocketing Higher Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 15.3% in the morning session after results from a Phase 3 trial showed that its experimental drug, Orforglipron, performed... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Top S&P500 movers in Thursday's pre-market session
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Nvidia CEO Jensen Huang Visits Beijing After Trump Administration’s Ban On H20 Chip Sales To China
Before this, Nvidia’s H100 and A100 chips, which are more powerful than the H20 chip, were banned from being sold in China. 
Via Stocktwits
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Interest Rates Political
ECB Cuts Interest Rates For 7th Time In A Row As Trump Tariffs Spark Growth Fears – Warns Of ‘Tightening’ Impact From Trade Tensions
The central bank acknowledged that the euro area economy has been building up some resilience against global shocks, but the growth outlook has deteriorated due to rising trade tensions. 
Via Stocktwits
Topics ETFs Economy Government
Exposures Economy Interest Rates Political
1 S&P 500 Stock for Long-Term Investors and 2 to Turn Down
While the S&P 500 includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds. 
Via StockStory
Topics Stocks
Exposures US Equities
Eli Lilly’s Weight Loss Pill Succeeds In Phase 3 Trials On Type-2 Diabetes Patients
The company says orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to successfully complete a Phase 3 trial. 
Via Stocktwits
Topics Economy Government Stocks
Exposures Interest Rates Political US Equities
Eli Lilly Stock Rockets On Weight-Loss Pill Progress
Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars
Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable safety profile. 
Via Benzinga
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Exposures Political
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.